BioSpace News Archive

Stretcher chairs, used to carry patients from one place to another within and outside of a health care center conveniently, are witnessing a constant increase in demand.

The outsourcing of biologics has seen a tremendous rise over the years prominently due to its benefits such as decreased investment in drug development and large-scale provision of manufacturing capabilities.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,946,027 to the Company on March 16, 2021. Tianeptine oxalate is the active pharmaceutical ingredient of Tonix’s development candidate, TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablet).

Received FDA IDE Approval for Pivotal Study of C-Scan® Company on track to initiate a U.S. pivotal study of C-Scan in late 2021

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company , today announced an exclusive interview featuring Robb Knie , CEO, airing on The RedChip Money Report on the Bloomberg Television U.S. on Saturday, March 20th at 7 p.m. local time across the United States .

U.S. FDA has assigned a target action date of January 28, 2022 Application based on results from the Phase 3 EXPLORER-HCM trial

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets’ Life Sciences and MedTech Investor Forum on Wednesday, March 24 at 2:00 p.m. ET.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (“TBI”) in a rodent model of TBI

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer and Michael Panzara, MD, MPH, Chief Medical Officer and Head of Therapeutics Discovery and Development are scheduled to participate virtually in an analyst-led fireside chat at the Third Annual Stifel CNS Day